209 related articles for article (PubMed ID: 22545664)
1. Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry.
Francis JN; Redman JS; Eckert DM; Kay MS
Bioconjug Chem; 2012 Jun; 23(6):1252-8. PubMed ID: 22545664
[TBL] [Abstract][Full Text] [Related]
2. Characterization of resistance to a potent D-peptide HIV entry inhibitor.
Smith AR; Weinstock MT; Siglin AE; Whitby FG; Francis JN; Hill CP; Eckert DM; Root MJ; Kay MS
Retrovirology; 2019 Oct; 16(1):28. PubMed ID: 31640718
[TBL] [Abstract][Full Text] [Related]
3. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance.
Welch BD; Francis JN; Redman JS; Paul S; Weinstock MT; Reeves JD; Lie YS; Whitby FG; Eckert DM; Hill CP; Root MJ; Kay MS
J Virol; 2010 Nov; 84(21):11235-44. PubMed ID: 20719956
[TBL] [Abstract][Full Text] [Related]
4. Potent D-peptide inhibitors of HIV-1 entry.
Welch BD; VanDemark AP; Heroux A; Hill CP; Kay MS
Proc Natl Acad Sci U S A; 2007 Oct; 104(43):16828-33. PubMed ID: 17942675
[TBL] [Abstract][Full Text] [Related]
5. Evolved Proteins Inhibit Entry of Enfuvirtide-Resistant HIV-1.
Ikeda T; Tennyson RL; Walker SN; Harris RS; McNaughton BR
ACS Infect Dis; 2019 Apr; 5(4):634-640. PubMed ID: 30811933
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.
Eckert DM; Malashkevich VN; Hong LH; Carr PA; Kim PS
Cell; 1999 Oct; 99(1):103-15. PubMed ID: 10520998
[TBL] [Abstract][Full Text] [Related]
7. Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent d-peptide HIV entry inhibitor.
Nishimura Y; Francis JN; Donau OK; Jesteadt E; Sadjadpour R; Smith AR; Seaman MS; Welch BD; Martin MA; Kay MS
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22436-22442. PubMed ID: 32820072
[TBL] [Abstract][Full Text] [Related]
8. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
9. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
[TBL] [Abstract][Full Text] [Related]
10. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
Eckert DM; Kim PS
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11187-92. PubMed ID: 11572974
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and Chemical Synthesis Optimization of a Potent d-Peptide HIV Entry Inhibitor Suitable for Extended-Release Delivery.
Redman JS; Francis JN; Marquardt R; Papac D; Mueller AL; Eckert DM; Welch BD; Kay MS
Mol Pharm; 2018 Mar; 15(3):1169-1179. PubMed ID: 29436835
[TBL] [Abstract][Full Text] [Related]
12. Design of highly potent HIV fusion inhibitors based on artificial peptide sequences.
Shi W; Cai L; Lu L; Wang C; Wang K; Xu L; Zhang S; Han H; Jiang X; Zheng B; Jiang S; Liu K
Chem Commun (Camb); 2012 Dec; 48(94):11579-81. PubMed ID: 23093045
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics modeling the synthetic and biological polymers interactions pre-studied via docking: anchors modified polyanions interference with the HIV-1 fusion mediator.
Tsvetkov VB; Serbin AV
J Comput Aided Mol Des; 2014 Jun; 28(6):647-73. PubMed ID: 24862639
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike.
Eggink D; de Taeye SW; Bontjer I; Klasse PJ; Langedijk JPM; Berkhout B; Sanders RW
J Virol; 2016 Dec; 90(23):10587-10599. PubMed ID: 27654295
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target.
Qiu Z; Chong H; Yao X; Su Y; Cui S; He Y
AIDS; 2015 Jun; 29(9):1015-24. PubMed ID: 26125136
[TBL] [Abstract][Full Text] [Related]
16. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core.
Zhou G; Ferrer M; Chopra R; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Harrison SC; Wiley DC
Bioorg Med Chem; 2000 Sep; 8(9):2219-27. PubMed ID: 11026535
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
Yi HA; Fochtman BC; Rizzo RC; Jacobs A
Curr HIV Res; 2016; 14(3):283-94. PubMed ID: 26957202
[TBL] [Abstract][Full Text] [Related]
18. Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.
Geng X; Liu Z; Yu D; Qin B; Zhu Y; Cui S; Chong H; He Y
Viruses; 2019 Jul; 11(7):. PubMed ID: 31277353
[TBL] [Abstract][Full Text] [Related]
19. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
[TBL] [Abstract][Full Text] [Related]
20. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
